Last edition
News about "Inference platform "
Variant Bio partners with Boehringer Ingelheim for Research on Kidney Disease
The multi-year collaboration with Boehringer Ingelheim will leverage Variant Bio’s AI-powered Inference platform to identify novel kidney disease drug targets, with financial terms including upfront, licence and milestone payments that could exceed USD 120 million.
Inference Platform | 08/01/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members